Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-076710
Filing Date
2025-08-14
Accepted
2025-08-14 16:27:56
Documents
75
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0252595-10q_aditxt.htm   iXBRL 10-Q 1508984
2 CERTIFICATION ea025259501ex31-1_aditxt.htm EX-31.1 10601
3 CERTIFICATION ea025259501ex31-2_aditxt.htm EX-31.2 10751
4 CERTIFICATION ea025259501ex32-1_aditxt.htm EX-32.1 5209
  Complete submission text file 0001213900-25-076710.txt   8237625

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE adtx-20250630.xsd EX-101.SCH 76033
6 XBRL CALCULATION FILE adtx-20250630_cal.xml EX-101.CAL 43030
7 XBRL DEFINITION FILE adtx-20250630_def.xml EX-101.DEF 408950
8 XBRL LABEL FILE adtx-20250630_lab.xml EX-101.LAB 694506
9 XBRL PRESENTATION FILE adtx-20250630_pre.xml EX-101.PRE 425464
78 EXTRACTED XBRL INSTANCE DOCUMENT ea0252595-10q_aditxt_htm.xml XML 916927
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39336 | Film No.: 251219812
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)